Deutsche Bank Reiterates Hold on Abbott Laboratories Following Release of MitraClip FDA Panel Documents

In a report published Monday, Deutsche Bank analyst Kristen Stewart reiterated a Hold rating and $33.00 price target on Abbott Laboratories (NYSE: ABT ). In the report, Stewart noted, “The FDA has released panel documents for MitraClip, which will be evaluated by an FDA Circulatory Systems Devices Panel on March